3-Arylidene-N-hydroxyoxindoles

A New Class of Compounds Endowed with Antitumor Activity

Loana Musso, Raffaella Cincinelli, Valentina Zuco, Michelandrea De Cesare, Franco Zunino, Anna Lucia Fallacara, Maurizio Botta, Sabrina Dallavalle

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A series of compounds containing the N-hydroxyoxindole scaffold were synthesized and evaluated for antitumor activity. The compounds showed potent antiproliferative activity against the wild-type p53 IGROV-1 ovarian carcinoma cell line and considerably lower efficacy against the mutant IGROV-1/Pt1 subline that lacks p53 function. The differential response of ovarian carcinoma cells depending on p53 status was also reflected in the varied susceptibility to apoptosis of the treated cell lines. These results support a role for the p53 transcription factor as a determinant of cytotoxicity. The therapeutic potential of the most promising compound of the series was evaluated in the treatment of an IGROV-1 xenograft growing as ascitic tumor in mice. Using intraperitoneal administration, daily treatment with the compound for four weeks produced a significant delay in the onset of ascites.

Original languageEnglish
Pages (from-to)1700-1704
Number of pages5
JournalChemMedChem
DOIs
Publication statusPublished - Aug 19 2016

Fingerprint

Cells
Carcinoma
Cell Line
Ascites
Heterografts
Transcription Factors
Cytotoxicity
Apoptosis
Scaffolds
Tumors
Neoplasms
Therapeutics

Keywords

  • antiproliferative activity
  • antitumor agents
  • apoptosis
  • N-hydroxyoxindole
  • p53

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Musso, L., Cincinelli, R., Zuco, V., De Cesare, M., Zunino, F., Fallacara, A. L., ... Dallavalle, S. (2016). 3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity. ChemMedChem, 1700-1704. https://doi.org/10.1002/cmdc.201600225

3-Arylidene-N-hydroxyoxindoles : A New Class of Compounds Endowed with Antitumor Activity. / Musso, Loana; Cincinelli, Raffaella; Zuco, Valentina; De Cesare, Michelandrea; Zunino, Franco; Fallacara, Anna Lucia; Botta, Maurizio; Dallavalle, Sabrina.

In: ChemMedChem, 19.08.2016, p. 1700-1704.

Research output: Contribution to journalArticle

Musso, L, Cincinelli, R, Zuco, V, De Cesare, M, Zunino, F, Fallacara, AL, Botta, M & Dallavalle, S 2016, '3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity', ChemMedChem, pp. 1700-1704. https://doi.org/10.1002/cmdc.201600225
Musso L, Cincinelli R, Zuco V, De Cesare M, Zunino F, Fallacara AL et al. 3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity. ChemMedChem. 2016 Aug 19;1700-1704. https://doi.org/10.1002/cmdc.201600225
Musso, Loana ; Cincinelli, Raffaella ; Zuco, Valentina ; De Cesare, Michelandrea ; Zunino, Franco ; Fallacara, Anna Lucia ; Botta, Maurizio ; Dallavalle, Sabrina. / 3-Arylidene-N-hydroxyoxindoles : A New Class of Compounds Endowed with Antitumor Activity. In: ChemMedChem. 2016 ; pp. 1700-1704.
@article{372c126c700c4bba9108b70a743d4d9c,
title = "3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity",
abstract = "A series of compounds containing the N-hydroxyoxindole scaffold were synthesized and evaluated for antitumor activity. The compounds showed potent antiproliferative activity against the wild-type p53 IGROV-1 ovarian carcinoma cell line and considerably lower efficacy against the mutant IGROV-1/Pt1 subline that lacks p53 function. The differential response of ovarian carcinoma cells depending on p53 status was also reflected in the varied susceptibility to apoptosis of the treated cell lines. These results support a role for the p53 transcription factor as a determinant of cytotoxicity. The therapeutic potential of the most promising compound of the series was evaluated in the treatment of an IGROV-1 xenograft growing as ascitic tumor in mice. Using intraperitoneal administration, daily treatment with the compound for four weeks produced a significant delay in the onset of ascites.",
keywords = "antiproliferative activity, antitumor agents, apoptosis, N-hydroxyoxindole, p53",
author = "Loana Musso and Raffaella Cincinelli and Valentina Zuco and {De Cesare}, Michelandrea and Franco Zunino and Fallacara, {Anna Lucia} and Maurizio Botta and Sabrina Dallavalle",
year = "2016",
month = "8",
day = "19",
doi = "10.1002/cmdc.201600225",
language = "English",
pages = "1700--1704",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - 3-Arylidene-N-hydroxyoxindoles

T2 - A New Class of Compounds Endowed with Antitumor Activity

AU - Musso, Loana

AU - Cincinelli, Raffaella

AU - Zuco, Valentina

AU - De Cesare, Michelandrea

AU - Zunino, Franco

AU - Fallacara, Anna Lucia

AU - Botta, Maurizio

AU - Dallavalle, Sabrina

PY - 2016/8/19

Y1 - 2016/8/19

N2 - A series of compounds containing the N-hydroxyoxindole scaffold were synthesized and evaluated for antitumor activity. The compounds showed potent antiproliferative activity against the wild-type p53 IGROV-1 ovarian carcinoma cell line and considerably lower efficacy against the mutant IGROV-1/Pt1 subline that lacks p53 function. The differential response of ovarian carcinoma cells depending on p53 status was also reflected in the varied susceptibility to apoptosis of the treated cell lines. These results support a role for the p53 transcription factor as a determinant of cytotoxicity. The therapeutic potential of the most promising compound of the series was evaluated in the treatment of an IGROV-1 xenograft growing as ascitic tumor in mice. Using intraperitoneal administration, daily treatment with the compound for four weeks produced a significant delay in the onset of ascites.

AB - A series of compounds containing the N-hydroxyoxindole scaffold were synthesized and evaluated for antitumor activity. The compounds showed potent antiproliferative activity against the wild-type p53 IGROV-1 ovarian carcinoma cell line and considerably lower efficacy against the mutant IGROV-1/Pt1 subline that lacks p53 function. The differential response of ovarian carcinoma cells depending on p53 status was also reflected in the varied susceptibility to apoptosis of the treated cell lines. These results support a role for the p53 transcription factor as a determinant of cytotoxicity. The therapeutic potential of the most promising compound of the series was evaluated in the treatment of an IGROV-1 xenograft growing as ascitic tumor in mice. Using intraperitoneal administration, daily treatment with the compound for four weeks produced a significant delay in the onset of ascites.

KW - antiproliferative activity

KW - antitumor agents

KW - apoptosis

KW - N-hydroxyoxindole

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=84983239017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983239017&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201600225

DO - 10.1002/cmdc.201600225

M3 - Article

SP - 1700

EP - 1704

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

ER -